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•The PAWSS questionnaire was administered to Adults (18 years and older) treated in the 
Cooper ED and Trauma Admitting and admitted into Cooper University Hospital.
•Alcohol withdrawal symptoms were measured and documented using the Glasgow Modified 
Alcohol Withdrawal Scale (GMAWS) within 48 hours of admission.
•Demographic information such as age, gender, ethnicity, and visit information was obtained.
•A positive PAWSS was considered a score of 4 or greater.
•Patients were considered to have undergone alcohol withdrawal if they had AWS as a primary 
diagnosis or they scored a 2 or greater on the GMAWS.
PAWSS
Validation of the Prediction of Alcohol Withdrawal Severity Scale
Alexander Padron, MS4; Matthew Salzman, MD
•The ability to accurately predict which patients are likely to go into complicated alcohol 
withdrawal would significantly decrease the amount of in-hospital morbidity and mortality as 
well as the increased costs associated with increased lengths of hospitalization.
•Alcohol use disorder is one of the largest substance abuse problems in America, with a twelve 
month and lifetime prevalence of 13.9% and 29.1% respectively.
•In a third of all hospitalized patients there is a strong likelihood that they possess an alcohol 
use disorder.
•On average about 20% of patients will develop symptoms of complicated alcohol withdrawal, 
exhibiting seizures and delirium tremens (DTs) and associated mortality.
•The Prediction of Alcohol Withdrawal Severity Scale (PAWSS) is the first screening tool 
developed for Alcohol Withdrawal Syndromes (AWS). The PAWSS pilot study reported a 
sensitivity and specificity of 100% with a sample size of 17. This study will reexamine this tool's 
sensitivity and specificity with a larger sample size.
Introduction
•The PAWSS was shown to have a sensitivity of 46%, and a specificity of 97%. With a positive 
predictive value of 79% and a negative predictive value of 88%.
•A total of 19% of the patients surveyed underwent symptoms of moderate to severe AWS, 
agreeing with the reported incidence in other studies.
•Patients who were predicted by the PAWSS to develop AWS tended to be younger and were 
more likely to be male. However the difference was not significant.
•During the course of the study 54% of the patients were admitted into the general floor, 27% 
were admitted to Telemetry/PCU, 8% were admitted to step down/trauma, and 9% were 
admitted into the ICU.
•White ethnicity made up 64.6% of the total participants.
•Except for one, all patients that scored “+” on the PAWSS received treatment. Of those 
patients 74% received benzodiazepines, and 26% received anticonvulsants.
Methodology
Discussion
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•With a PPV of 79% and a NPV of 88% the PAWSS can be used as an effective tool to predict alcohol 
withdrawal but it is important to be aware of its limitations and how it can be further improved.
•This survey tool could be further refined by narrowing down the most pertinent questions as well as 
redefining the threshold questions.
•Possible reasons for the false positives could be due to the way the PAWSS threshold questions are worded. 
The question asks if alcohol has been consumed in the past 30 days, which can result in patient being 
outside of the alcohol withdrawal timeline.
•Patients could also have been so ill as to mask their symptoms of AWS, such as in patients admitted to the 
ICU.
•The GMAWS itself does not account for all the symptoms of AWS, such as autonomic instability, and possess 
subjective categories such as anxiousness.  
•Along with refining this tool there needs to be a push for better recognition of AWS. Previous literature has 
shown that even experienced doctors have trouble recognizing AWS consistently. This was exemplified in our 
study when two patients had AWS and a primary diagnosis yet scored a 0 on the GMAWS. Though this may 
be due to missing the window of symptoms or the treatment being provided prior to testing.
Conclusion
Study ResultsDemographic Results
Calculating specificity, sensitivity, positive predictive value (PPV), and negative predictive value (NPV).
Sensitivity = TP/”AWS +” = 27/58 = 46%
Specificity = TN/”AWS -” =  243/250 = 97%
PPV = TP/”PAWSS +” = 27/34 = 79%
NPV = TN/”PAWSS -” = 243/274 = 88%
Alcohol Withdrawal Timeline
Patient Groups (n) Age, Average (SD) % Male
Negative PAWSS screen (572) 56 (17) 44.20%
PAWSS 0-3 (274) 53 (16) 55.50%
PAWSS ≥ 4 (34) 45 (13) 73.50%
AWS “+” (n) AWS “-” (n) Total
PAWSS “+” True positive (TP) 27 False positives (FP) 7 All PAWSS “+” 34
PAWSS “-” False negatives (FN) 31 True negatives (TN) 243 ALL PAWSS “-” 274
Total Patients with AWS (AWS “+”) 58 Patients with no AWS (AWS “-”) 250 Total Patients 308
